Solid‐state‐cultured mycelium of Antrodia camphorata exerts potential neuroprotective activities against 6‐hydroxydopamine‐induced toxicity in PC12 cells.

Antrodia camphorata (A. camphorata) is an edible fungus containing various bioactive compounds generally used for health benefits. This study aimed to explore the potential neuroprotective activities of solid‐state‐cultured mycelium of A. camphorata (SCMAC) against Parkinson's disease (PD), as well as the underlying mechanism using an in vitro 6‐hydroxydopamine (6‐OHDA)‐induced PC12 cell model. The results showed that SCMAC extracts alleviated cell toxicity induced by 6‐OHDA and the loss of dopaminergic neurons, which was confirmed by the increase of cell viabilities, inhibition of cell apoptosis, the upregulation of tyrosine hydroxylase (TH) and dopamine transporter (DAT) levels and the downregulation of α‐Synuclein level. After purification, 11 compounds were identified by the NMR technique, including a quinone, four phenolic acid derivatives, three ubiquinone derivatives, two alkaloids, and a triterpenoid. The present study suggests that SCMAC could be an attractive candidate for the prevention or treatment of PD. Practical applications: Parkinson's disease seriously affects the lifetime and quality of the elder population for a long history. Long‐term consumption of L‐DOPA will result in side effects, such as developing abnormal involuntary movements called dyskinesia. This study showed that natural SCMAC extracts could be a potential therapeutic agent for the treatment of neurodegenerative disorder. [ABSTRACT FROM AUTHOR]